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ABSTRACT
Objective: The aim of this study was to investigate the factors associated with coronary stent restenosis and if there is an association between 
plasma asymmetric dimethylarginine (ADMA) levels and stent restenosis.
Methods: Ninety-one patients, who had a history of coronary bare metal stent implantation due to any cause in the last one year period, were 
admitted to this observational cross-sectional study. Coronary angiography was performed to all patients and quantitative angiography was 
used to determine the presence of stent restenosis. Laboratory parameters and angiographic features that contribute to stent restenosis were 
evaluated. Plasma ADMA levels were measured by using high performance liquid chromatography. Logistic regression analysis was used to 
determine the independent factors of stent restenosis.
Results: Angiographic restenosis was found in 35 patients (38.5%). Stent diameter (p=0.038) and left ventricular ejection fraction (p=0.023) were 
lower and stent implantation history due to acute coronary syndrome (p=0.029), plasma ADMA level (5.0±1.8x10-4 mmol/L vs. 3.9±1.0x10-4 
mmol/L, p=0.001), C-reactive protein concentration (p=0.016), white blood cell count (p=0.044) and stent length (p=0.005) were higher in patients 
with restenosis. Plasma ADMA level (β=0.536; OR: 1.710; CI: 1.022-2.861; p=0.041), C-reactive protein concentration (β=0.062; OR: 1.064; CI: 1.003-
1.129; p=0.041), stent diameter (β=-3.047; OR: 0.048; CI: 0.007-0.313; p=0.002) and length (β=0.165; OR: 1.179; CI: 1.036-1.343; p=0.013) were found 
to be the independent predictors of stent restenosis in logistic regression analysis.
Conclusion: We conclude that plasma ADMA levels may be used as a novel marker for stent restenosis beyond the classic stent restenosis 
markers. (Anadolu Kardiyol Derg 2014; 14: 491-7)
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beyond the classic predictors of stent restenosis?
Introduction
In recent years, stents are widely used for the treatment of 
coronary artery disease. During the wide spread usage of coro-
nary stent implantation, stent restenosis was found to be the 
major problem related to this intervention. Neointimal hyperpla-
sia composed of vascular smooth muscle cells and the matrix is 
the mainstay of stent restenosis (1). Nitric oxide (NO) was con-
verted from L-arginine by nitric oxide synthase (NOS) and 
released from intact endothelium (2, 3). Nitric oxide inhibits 
vascular smooth muscle cell proliferation and prevents neointi-
mal hyperplasia. Thanyasiri et al. (4) showed that endothelium-
dependent coronary artery dilatation was reduced in subjects 
with restenosis after percutaneous coronary intervention. It has 
also been shown that the NO prevents the development of reste-
nosis after percutaneous transluminal coronary angioplasty 
(PTCA) by inhibiting the formation of mitogenic substances 
resulted from injured endothelial tissue and the adhesion of 
leukocyte and thrombocytes (5, 6). Asymmetric dimethylarginine 
(ADMA) is a potent competitive inhibitor of NOS and occurs dur-
ing protein degradation of arginine residues (7, 8). As a result of 
NOS inhibition by ADMA, NO formation and therefore its protec-
tive effects against the stent restenosis diminishes.
Many factors contribute to stent restenosis. Stent diameter 
and length were well known predictors for stent restenosis but 
there is not enough knowledge about ADMA and its role on stent 
restenosis. In recent years few studies reveal a link between 
ADMA and stent restenosis due to its role on NO formation 
(9-11). Derkacz et al. (9) concluded that pre-procedural elevated 
plasma ADMA levels increases the risk of restenosis in patients 
who underwent coronary angioplasty and stenting with bare 
metal stents. Khalifa et al. (10) found that the patients who devel-
oped stent restenosis had an increase in ADMA levels following 
coronary stenting. Arı et al. (11) found that the plasma levels of 
ADMA obtained before the procedure predict the development 
of restenosis and major adverse cardiac events in patients who 
underwent elective percutaneous transluminal coronary angio-
plasty and bare metal stent procedures. All of these studies 
attempted to evaluate the predictive value of ADMA on stent 
restenosis but more data is still needed in this regard. The aim of 
this study was to investigate the factors associated with coro-
nary stent restenosis and also decide to evaluate the associa-
tion between ADMA levels and stent restenosis on the patients 
with coronary stent and who need a diagnostic coronary angi-
ography due to symptoms or high risk positive stress tests or 
laboratory parameters. 
Methods
This study was designed as an observational cross-section-
al study and has been approved by the Başkent University 
Ethical Committee. The patients who were admitted to our emer-
gency service or outpatient clinics with a history of coronary 
bare metal stent implantation in the last one year period were 
evaluated for the study participation. Exclusion criteria were 
defined as chronic renal failure, chronic liver disease, cerebro-
vascular event in the last year, severe peripheral arterial dis-
ease, uncontrolled diabetes mellitus (HbA1c >%7), uncontrolled 
hypertension (systolic blood pressure >140 mm Hg or diastolic 
blood pressure >90 mm Hg regardless of hypertension status or 
preexisting antihypertensive medication use) (12), clinical hyper-
thyroidism, erectile dysfunction and pulmonary hypertension 
(mean pulmonary arterial pressure >30 mm Hg). Patients with 
drug eluting stents (DES) were also excluded because DES have 
different mechanisms of restenosis and might be seen after a 
long time period (delayed restenosis). Ninety-one patients with 
recurrent angina pectoris under optimal medication or high risk 
positive stress tests or acute coronary syndrome were enrolled 
to the study. All patients were informed about the study protocol 
and written informed consent was obtained. 
The demographic characteristics, cardiovascular risk fac-
tors and the medication history of the patients were recorded 
and all underwent an extensive physical examination. Patients 
with two consecutive fasting serum glucose measurements > 
126 mg/dL (13) or those on oral antidiabetic drug and/or insulin 
were diagnosed as diabetic. Hypertensive patients with the sys-
tolic blood pressure <140 mm Hg and diastolic blood pressure 
<90 mm Hg on physical examination under drug therapy were 
diagnosed as controlled hypertensive. Hyperlipidemia was 
defined as LDL cholesterol >100 mg/dL, HDL cholesterol <40 mg/
dL or triglyceride >150 mg/dL or usage of lipid lowering drug 
therapy (14). Body mass index (BMI) was calculated by division 
of weight to height’s square (kg/m2) and patients with BMI >30 
kg/m2 were diagnosed as obese (15).
Serum levels of total cholesterol, low density lipoprotein 
(LDL) cholesterol, high density lipoprotein (HDL) cholesterol, tri-
glyceride, glucose, creatinine, C-reactive protein and hemogram 
were determined by using commercial tests (Belliver Industrial 
Estate, Plymouth, UK) after 8 hours of fasting period. 
Percutaneous coronary intervention views and reports of the 
patients were analyzed cautiously by one experienced cardiolo-
gist and the factors (predilatation, stent diameter, stent length, 
oversizing, undersizing, residue stenosis) that might contribute 
to stent restenosis were noted.
Electrocardiography and echocardiography were performed 
to all patients. Especially left ventricle ejection fraction, left ven-
tricle hypertrophy and pulmonary blood pressures were calcu-
lated cautiously by one experienced echocardiographer.
After these steps, an elective coronary angiography was 
assessed for the patients. Blood samples (10 mL) were collected 
into the ethylenediaminetetraacetic acid containing tubes from 
femoral arterial sheath before coronary angiography was per-
formed. Whole blood samples were centrifuged immediately in 
biochemistry laboratory at 3000 g for 10 minutes. Each plasma 
samples were put into two Eppendorf tubes (Labor Teknik, 
İstanbul, Turkey) by using a plastic pipe and stored in a deep 
freezer at -80 degree (Celsius) until analysis. One of the plasma 
samples was analyzed in biochemistry laboratory and the other 
sample was stored in the freezer for the backup. 
Coronary angiographic examination was performed after 
local anesthesia by employing the modified Seldinger technique 
through the femoral artery. All coronary arteries were visualized 
at right and left anterior oblique projections with caudal and 
cranial angulations and left lateral projection (Philips, Artis zee, 
Munich, Germany). Left ventriculography was also performed at 
right and left anterior oblique projections. Iohexol was used in 
coronary angiography and left ventriculography as the contrast 
agent. Coronary angiography views were assessed by two expe-
rienced cardiologists who had no knowledge about the patients’ 
clinical demographics and laboratory parameters. The degree of 
coronary stenosis was determined at the projection which 
shows the stenosis more severe. Quantitative coronary angiog-
raphy was used to determine the severity of stenosis and angio-
graphic restenosis is defined as ≥50% luminal narrowing (16). 
Plasma ADMA levels were analyzed by using high perfor-
mance liquid chromatography (HPLC). The method includes 
reversed-phase HPLC analysis by using fluorescence detection 
(Shimadzu LC 10A fluorescent detector, Japan) in a high-perfor-
mance liquid chromatography system (Shimadzu RF 10XL, 
Japan). The plasma concentrations of ADMA were measured by 
HPLC with precolumn derivatization with o-phthaldialdehyde 
(OPA) and 3-mercaptopropionic acid. Samples and standards 
were incubated with OPA reagent for exactly 30 s before injec-
tion into the HPLC system (17).
Statistical analysis
Statistical analyses were performed by using the statistical 
program for the social sciences (SPSS) version 15.0 (Chicago, IL, 
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USA). Data were submitted to a frequency distribution analysis 
by Kolmogorov-Smirnov’s test. Values displaying normal distri-
bution were expressed as the mean (standard deviation; SD) 
and values with skewed distribution were expressed as median 
(interquartile range). While comparing parametric variables 
‘Independent Samples T’ test and in nonparametric variables 
‘Mann-Whitney U’ test were used. Categorical variables were 
compared using chi-square tests, or if small expected cell fre-
quencies, exact tests. To determine the independent factors of 
stent restenosis, “Logistic Regression Analysis” method was 
used for significant variables which were found in binary com-
parisons. The p values less than 0.05 were accepted as statisti-
cally significant.
Results
The patients who had a history of coronary stent implanta-
tion within one year (9.0±1.7 months) and planned to undergo an 
elective coronary angiography in our center were evaluated for 
study participation. 91 patients, 72 (79.1%) men, 19 women 
(20.9%) and mean age 58.96±8.72 years were included in the 
study. 32 patients were diabetic (35.2%), 62 (68.1%) had hyper-
tension and 77 (84.6%) had hyperlipidemia. Out of 91 patients, 35 
had an established stent restenosis after coronary angiography. 
The time period after stent implantation to coronary angiography 
had a mean 8.7±1.8 months in patients with stent restenosis. 
1. Clinical characteristics/ Laboratory parameters and stent 
restenosis:
When we compared the clinical characteristics of the 
patients, only the incidence of stent implantation due to acute 
coronary syndrome was significantly higher in the patients with 
restenosis than the patients without restenosis (77.1% vs. 55.4%; 
p=0.029, respectively). There were no association between age 
and plasma ADMA levels (p=0.524 for women and p=0.260 for 
men). There was no significant difference between two groups 
according to the usage of medications and also between plasma 
ADMA levels and the type of medication (all p values >0.05).
Among the laboratory parameters studied, patients with 
restenosis has significantly higher plasma ADMA levels than the 
patients without restenosis (5.1±1.8x10-4 mmol/L vs. 3.9±1.0x 10-4 
mmol/L; p=0.001) (Fig. 1). Also serum C-reactive protein levels 
[6.0 (11.1) mg/L vs. 1.9 (3.0) mg/L; p=0.016] and white blood cell 
count (8.036±1.964×103/μL vs. 7.238±1.530×103/μL; p=0.044) were 
higher and left ventricle ejection fraction was lower (49.6±10.4% 
vs. 54.1±8.2%; p=0.023) in the patients with restenosis than the 
patients without restenosis. All the clinical characteristics and 
laboratory parameters of patients with and without stent reste-
nosis were summarized in Table 1.
2. Relationship between plasma ADMA levels and clinical 
characteristics/Laboratory parameters: 
There was no significant relationship between plasma 
ADMA levels and clinical characteristics. But plasma ADMA 
levels tended to be higher in diabetic patients (n=32) compared 
  Restenosis (+) Restenosis (-) 
Clinical characteristics n=35 n=56 P
Age, years 57.5±7.2 59.8±9.5 0.139
Gender, male, (%) 30 (85.7) 42 (75.0) 0.169
Diabetes mellitus, (%) 13 (37.1) 19 (33.9) 0.463
Hypertension, (%) 22 (62.9) 40 (71.4) 0.266
Hyperlipidemia, (%) 31 (88.6) 46 (82.1) 0.304
Smoking, (%) 19 (54.3) 30 (53.6) 0.560
Alcohol consumption, (%) 1 (2.9) 4 (7.1) 0.359
Family history of CAD, (%) 16 (45.7) 27 (48.2) 0.494
History of PAD, (%) 2 (5.7) 0 (0.0) 0.145
Presentation with ACS  27 (77.1) 31 (55.4) 0.029 
before stent implantation, (%) 
BMI > 30 kg/m2, (%) 6 (17.1) 13 (23.2) 0.338
Medications   
Acetylsalicylic acid, (%) 32 (91.4) 48 (85.7) 0.416
Beta blockers, (%) 26 (74.2) 45 (80.3) 0.496
ACEI/ARB, (%) 25 (71.4) 39 (69.6) 0.856
Calcium canal blockers, (%) 9 (25.7) 17 (30.3) 0.633
Statins, (%) 27 (77.1) 45 (80.3) 0.714
Nitrates, (%) 14 (40.0) 22 (39.3) 0.946
Laboratory parameters
Plasma ADMA, 10-4 mmol/L 5.1±1.8 3.9±1.0 0.001
Serum CRP, mg/L* 6.0 (11.1) 1.9 (3.0) 0.016
Serum glucose, mg/dL* 111.74 (38) 107.16 (17) 0.394
Serum HbA1c, %** 6.8±1.0 6.3±0.9 0.208
Serum creatinine, mg/dL* 1.00 (0.2) 0.93 (0.2) 0.06
Serum HDL cholesterol, mg/dL 40.1±11.0 43.3±8.5 0.139
Serum LDL cholesterol, mg/dL 101.2±25.3 91.6±25.8 0.088
Serum triglyceride, mg/dL 161.3±50.0 141.4±68.0 0.141
Serum AST, U/L 24±10 23±9 0.770
Serum ALT, U/L 28±17 24±11 0.217
Serum ALP, U/L 169±41 148±57 0.273
Serum GGT, U/L 35±20 26±13 0.078
Hemoglobin, g/dL 14.2±1.5 14.2±1.3 0.872
White blood cell, ×103/μL 8.036±1.964 7.238±1.530 0.044
Platelet, ×103/μL 242±54 241±86 0.982
Left ventricle EF, % 49.6±10.4 54.1±8.2 0.023
ACS - acute coronary syndrome; ADMA - asymmetric dimethylarginine; ALP - alkaline 
phosphatase; ALT - alanine aminotransferase; AST - aspartate aminotransferase; BMI - 
body mass index; BUN - blood urea nitrogen; CAD - coronary artery disease; CRP - 
C-reactive protein; EF - ejection fraction; GGT - gamma-glutamyl transferase; HDL - high 
density lipoprotein; LDL - low density lipoprotein; PAD - peripheral artery disease
Parametric; value given as mean±standard deviation 
*Non-parametric; value given as median (interquartile range) 
**Data for diabetic patients
Table 1. Clinical characteristics and laboratory parameters of patients 
with and without stent restenosis
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to nondiabetics (p=0.068) (Fig. 2). Also in hyperlipidemic patients 
a tendency for higher plasma ADMA levels were observed com-
pared to patients with normal lipid levels (p=0.053).
3. Stent /implantation procedure properties and stent reste-
nosis:
When we consider the properties of stent and the implanta-
tion procedure, we found that the stent length (16.05±5.14 mm vs. 
14.27±4.13 mm; p=0.047) was significantly higher and the stent 
diameter (2.81±0.33 mm vs. 3.00±0.39 mm; p=0.018) was signifi-
cantly lower in patients with stent restenosis. Predilatation his-
tory before stent implantation (67.4% vs. 47.8%; p=0.025) was 
also significantly higher in the patients with stent restenosis. 
The other properties of stent and implantation procedure were 
not significantly different between the patients with or without 
stent restenosis (Table 2).
4. Independent predictors of stent restenosis
Logistic regression analysis was used to determine the inde-
pendent predictors for the development of stent restenosis. The 
variables (plasma ADMA levels, CRP, white blood cell count, left 
ventricle ejection fraction, acute coronary syndrome clinic before 
stent implantation, stent diameter, stent length and predilatation 
before stent implantation) which were significantly (p<0.05) differ-
ent in patients with or without stent restenosis were evaluated by 
using backward elimination method. Plasma ADMA levels 
(β=0.536; OR: 1.710; CI: 1.022-2.861; p=0.041), CRP (β=0.062; OR: 
1.064; CI: 1.003-1.129; p=0.041), stent diameter (β=-3.047; OR: 0.048; 
CI: 0.007-0.313; p=0.002) and length (β=0.165; OR: 1.179; CI: 1.036-
1.343; p=0.013) were found to be the independent predictors of 
stent restenosis in logistic regression analysis (Table 3).
Discussion
In our study we found higher plasma ADMA levels in patients 
with stent restenosis than without stent restenosis and stent diam-
eter, stent length, CRP and ADMA were the independent predictor 
of stent restenosis. Our results indicate that plasma ADMA levels 
may be used to predict the development of stent restenosis. 
Restenosis is the most important problem that limits the suc-
cess of percutaneous coronary revascularization interventions 
in the long term. In 1980s, the high ratio of restenosis after bal-
loon angioplasty declined to 20-30% with the usage of bare metal 
stents and to 8-15% with the drug eluting stents in 2000s (18, 19).
Very complex molecular and cellular mechanisms play role 
in stent restenosis. Different growth factors/receptors, cyto-
kines, secondary messengers and proto-oncogenes mediate 
this process (20). Most important mechanism in the development 
of stent restenosis is neointimal hyperplasia. Since stent implan-
tation inhibits elastic recoil and negative remodeling by its 
mechanical effect, stent restenosis develops mainly by neointi-
mal hyperplasia (1, 21). The development rate of neointimal 
hyperplasia is higher in the first six months and continues in a 
lower rate for 3 years after stent implantation. Neointima basi-
cally contains proliferated smooth muscle cells and extracellu-
lar matrix (22, 23).
Nitric oxide is a potent vasodilator which converted from its 
precursor L-arginine by NOS and it released by intact endothe-
lium. Behind the potent vasodilator effect, NO also protects the 
healthy vessels against atherosclerosis and restenosis. This 
effect achieved by inhibition of smooth muscle cells’ migration 
and proliferation. Nitric oxide also inhibits leukocytes and plate-
lets’ adhesion, aggregation and reconstruction attend to throm-
bosis (2, 5, 24, 25).
After an injury on the vessel wall NO synthesis and its pro-
tecting effect against the restenosis decreases because of 
endothelial dysfunction. Lee et al. (26) showed that NO inhala-
tion decreases neointimal hyperplasia by 50% after angioplasty 
in rat vessels. Do et al. (27) reported that intima-media ratio was 
32-46% less with NO releasing stent implantation than bare 
metal stent on rabbit aorta. In a human study Suziki et al. (28) 
found that intramural L-arginine implementation after stent 
implantation decreases neointimal volume by 35% at the end of 
six months. As a result, all these studies show the effects of NO 
against the development of restenosis.
At 1992, ADMA was discovered as an endogenous inhibitor 
of NOS and was thought to have an effect on the dysfunction of 
L-arginine/nitric oxide pathway (29). Asymmetric dimethylargi-
nine inhibits NO production and high levels of ADMA causes 
superoxide radicals’ production instead of NO by endothelial 
NOS (30).
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  Restenosis (+) Restenosis (-) 
  n=35 n=56 P
Predilatation, % 24 (67.4) 26 (47.8) 0.025
Stent diameter, mm 2.81±0.33 3.00±0.39 0.018
Stent length, mm 16.05±5.14 14.27±4.13 0.047
Stent oversizing, % 2 (5.7) 4 (7.14) 0.366
Stent undersizing, % 3 (8.5) 4 (7.14) 0.404
Residual stenosis after PCI, % 1 (2.8) 3 (5.3) 0.260
PCI - percutaneous coronary intervention
Parametric; value given as mean±standard deviation 
Table 2. Properties of stent and stent implantation procedure in patients 
with and without stent restenosis
   Odds ratio   Confidence
  β (OR) P interval (CI)
Plasma ADMA 0.536 1.710 0.041 1.022-2.861
CRP 0.062 1.064 0.041 1.003-1.129
EF -0.064 0.938 0.065 0.877-1.004
Stent diameter -3.047 0.048 0.002 0.007-0.313
Stent lenght 0.165 1.179 0.013 1.036-1.343
ADMA - asymmetric dimethylarginine; CRP - C-reactive protein; EF - ejection fraction
Binary logistic regression analysis was used and Odd’s ratios and 95% confidence intervals 
were calculated for the risk factors of stent restenosis
Table 3. Independent predictors of stent restenosis
In our study we want to search ‘if there is any role of ADMA 
on stent restenosis beyond the classic stent restenosis mark-
ers’. We thought that if ADMA inhibits NO synthesis, also it 
decreases the inhibiting effects of NO on the development of 
stent restenosis. So we admitted the patients who had a history 
of stent implantation in the past year and had a clinical indica-
tion for coronary angiography to our study. We measured plasma 
ADMA levels in those patients and compared them with the 
clinical characteristics and the angiographic features.
When the clinical characteristics are considered, the key 
point for the development of restenosis is whether the patient’s 
clinic at the time of stent implantation was acute coronary syn-
drome or not. Cutlip et al. (18) studied 6.186 patients (6.219 lesions) 
pooled from several recently completed coronary stent trials and 
unstable angina was marked as an independent predictor of stent 
restenosis. Similar to these findings we found significantly higher 
rates of stent restenosis in patients with acute coronary syn-
drome presentation at the time of stent implantation.
Controversial data are displayed in literature on the relation-
ship between ADMA and diabetes mellitus. Most of the studies 
reported that plasma ADMA levels were higher in patients with 
type II diabetes mellitus but not higher in patients with type I 
diabetes mellitus (31). In our study, all diabetic patients had type 
II diabetes mellitus. Similar to literature we found a tendency for 
higher plasma ADMA levels in patients with diabetes mellitus 
compared to nondiabetic patients.
In literature there are many studies which support the pres-
ence of an inflammatory response against the stents after stent 
implantation. Almagor et al. (32) showed an inflammatory response 
with high CRP levels after stent implantation to patients who have 
stable angina pectoris. Xu et al. (33) also found that the CRP levels 
at both pre-percutaneous coronary intervention and follow-up 
were significantly correlated with stent restenosis. In our study, 
when we evaluated the laboratory parameters of the patients, we 
found significantly higher serum CRP levels and white blood cell 
count in the patients with restenosis. In a prospective study 
Kozinski et al. (34) highlighted that inflammatory response and 
elevated CRP levels were more prominent in the patients with 
stent restenosis and it is similar to our findings.
In a prospective study done by Derkacz et al. (9) it has been 
demonstrated that pre-procedural elevated plasma ADMA lev-
els increased the risk of restenosis in patients who underwent 
coronary angioplasty and stenting with bare metal stents. In our 
study we did not analyzed the plasma ADMA levels before stent-
ing. We analyzed the plasma ADMA levels at the time of control 
angiography and found higher plasma ADMA levels in patients 
with stent restenosis after restenosis developed. Khalifa et al. 
(10) found that the patients who developed stent restenosis had 
a 35% increase in ADMA levels following coronary stenting. This 
finding is similar to our study but they have enrolled 37 patients 
in that study. In our study we have enrolled 91 patients and this 
is statistically more powerful. Also Arı et al. (11) found that the 
plasma levels of ADMA obtained before the procedure predict 
the development of restenosis and major adverse cardiac 
events in patients who underwent elective percutaneous trans-
luminal coronary angioplasty and bare metal stent procedures. 
The results of this study were also in parallel with our findings. 
Study limitations
Coronary angiography was not routinely performed to every 
patient after stent implantation as control angiography. We per-
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Figure 1. Plasma asymmetric dimethylarginine in restenotic and non-
restenotic patients 
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Figure 2. Plasma asymmetric dimethylarginine in diabetic and non-
diabetic patients
ADMA - asymmetric dimethylarginine; DM - diabetes mellitus
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formed control angiography to patients presenting with recur-
rent angina pectoris under optimal medication or high risk posi-
tive stress tests or acute coronary syndrome. So the rate of 
stent restenosis was found to be higher in the present study 
than general population.
Measurement of NO and arginine levels might improve the 
results of this study but we were not able to measure these 
parameters.
Fractional flow reserve might be better to define the stent 
restenosis than quantitative angiography. But it was not feasible 
to every restenotic patient in our country.
Conclusion 
We conclude that plasma ADMA levels can be used as a 
novel marker for stent restenosis beyond the classic stent reste-
nosis markers. By reducing plasma ADMA levels or by increas-
ing NO synthesis, the development of stent restenosis may be 
prevented. Nevertheless, large randomized and controlled trials 
are needed to further clarify the effect of ADMA on the develop-
ment of stent restenosis. 
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